Management of musculoskeletal pain in patients with idiopathic pulmonary fibrosis: a review

  • Svetlana Kašiković Lečić Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia; and University of Novi Sad, Faculty of Medicine, Department of Internal Medicine, Novi Sad, Serbia https://orcid.org/0000-0002-4151-6121
  • Jovan Javorac Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia; University of Novi Sad, Faculty of Medicine, Department of Internal Medicine, Novi Sad, Serbia; and College of Vocational Studies for the Education of Preschool Teachers and Sports Trainers, Department of Biomedical Sciences, Subotica, Serbia https://orcid.org/0000-0002-8567-8974
  • Dejan Živanović College of Vocational Studies for the Education of Preschool Teachers and Sports Trainers, Department of Biomedical Sciences, Subotica, Serbia https://orcid.org/0000-0001-8232-9368
  • Aleksandra Lovrenski Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia; and University of Novi Sad, Faculty of Medicine, Department of Pathology, Novi Sad, Serbia https://orcid.org/0000-0002-5278-6194
  • Dragana Tegeltija Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia; and University of Novi Sad, Faculty of Medicine, Department of Pathology, Novi Sad, Serbia https://orcid.org/0000-0002-9269-6644
  • Jelena Zvekić Svorcan Special Hospital for Rheumatic Diseases, Novi Sad, Serbia; and University of Novi Sad, Faculty of Medicine, Department of Medical Rehabilitation, Novi Sad, Serbia https://orcid.org/0000-0002-3489-4351
  • Jadranka Maksimović Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia https://orcid.org/0000-0002-8215-7399
Keywords: IPF, dyspnea, cough, pain, treatment

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic, and fatal interstitial lung disease (ILD) of unknown etiology that primarily affects the elderly. Patients with IPF suffer from a heavy symptom burden and usually have a poor quality of life. Dyspnea and dry cough are predominant symptoms of IPF. Although pain is not considered one of the main symptoms of IPF, it can occur for a variety of reasons, such as hypoxia, coughing, muscle and nerve damage, deconditioning, and steroid use. The prevalence of pain in IPF patients varies greatly, ranging from around 30 to 80%, with the prevalence being estimated mostly among patients in the end-of-life period. It manifests itself in the form of muscle pain, joint discomfort, or back and chest pain. Approaches to the treatment of chronic musculoskeletal pain in patients with IPF include pharmacological and non-pharmacological measures that are also important to optimize the treatment of other symptoms (dyspnea and cough) and the optimal treatment of comorbidities. Given the scarcity of data on this symptom in the literature, this article summarizes what is currently known about the etiology and treatment of musculoskeletal pain in IPF.

Downloads

Download data is not yet available.

References


  1. Akiyama N, Fujisawa T, Morita T, Mori K, Yasui H, Hozumi H, et al. Palliative care for idiopathic pulmonary fibrosis patients: pulmonary physicians’ view. J Pain Symptom Manage 2020;60:933–40. doi: 10.1016/j.jpainsymman.2020.06.012

  2. Plantier L, Cazes A, Dinh-Xuan AT, Bancal C, Marchand-Adam S, Crestani B. Physiology of the lung in idiopathic pulmonary fibrosis. Eur Respir Rev 2018;27:170062. doi: 10.1183/16000617.0062-2017

  3. Diridollou T, Sohier L, Rousseau C, Angibaud A, Chauvin P, Gaignon T, et al. Idiopathic pulmonary fibrosis: significance of the usual interstitial pneumonia (UIP) CT-scan patterns defined in new international guidelines. Respir Med Res 2020;77:72–8. doi: 10.1016/j.resmer.2020.02.004

  4. Zou RH, Kass DJ, Gibson KF, Lindell KO. The role of palliative care in reducing symptoms and improving quality of life for patients with idiopathic pulmonary fibrosis: a review. Pulm Ther 2020;6:35–46. doi: 10.1007/s41030-019-00108-2

  5. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018;198:e44–68. doi: 10.1164/rccm.201807-1255ST

  6. Spagnolo P, Sverzellati N, Rossi G, Cavazza A, Tzouvelekis A, Crestani B, et al. Idiopathic pulmonary fibrosis: an update. Ann Med 2015;47: 15–27. doi: 10.3109/07853890.2014.982165

  7. Hewson T, McKeever TM, Gibson JE, Navaratnam V, Hubbard RB, Hutchinson JP. Timing of onset of symptoms in people with idiopathic pulmonary fibrosis. Thorax 2018;73:683–5. doi: 10.1136/thoraxjnl-2017-210177

  8. Rozenberg D, Sitzer N, Porter S, Weiss A, Colman R, Reid WD, et al. Idiopathic pulmonary fibrosis: a review of disease, pharmacological, and nonpharmacological strategies with a focus on symptoms, function, and health-related quality of life. J Pain Symptom Manage 2020;59:1362–78. doi: 10.1016/j.jpainsymman.2019.12.364

  9. Lancaster L, Bonella F, Inoue Y, Cottin V, Siddall J, Small M, et al. Idiopathic pulmonary fibrosis: physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. Respirology 2022;27:66–75. doi: 10.1111/resp.14154

  10. Vogiatzis I, Zakynthinos G, Andrianopoulos V. Mechanisms of physical activity limitation in chronic lung diseases. Pulm Med 2012;2012:634761. doi: 10.1155/2012/634761

  11. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. J Respir Crit Care Med 2015;192:e3–19. doi: 10.1164/rccm.201506-1063ST

  12. Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir Res 2019;20:59. doi: 10.1186/s12931-019-1020-3

  13. Pleasants R, Tighe RM. Management of idiopathic pulmonary fibrosis. Ann Pharmacother 2019;53:1238–48. doi: 10.1177/1060028019862497

  14. Caminati A, Madotto F, Conti S, Cesana G, Mantovani L, Harari S. The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities. Intern Emerg Med 2021;16:1793–802. doi: 10.1007/s11739-021-02651-w

  15. Caminati A, Lonati C, Cassandro R, Elia D, Pelosi G, Torre O, et al. Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue. Eur Respir Rev. 2019;28:190044. doi: 10.1183/16000617.0044-2019

  16. Kang J, Song JW. Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis. Sci Rep 2021;11:17824. doi: 10.1038/s41598-021-97396-z

  17. Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, et al. Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis. N Eng J Med 2018;379:1722–31. doi: 10.1056/NEJMoa1811737

  18. Kreuter M, Raghu G. Gastro-oesophageal reflux and idiopathic pulmonary fibrosis: the heart burn in patients with IPF can no longer be silent. Eur Respir J 2018;51:1800921. doi: 10.1183/13993003.00921-2018

  19. Koo HJ, Do KH, Lee JB, Alblushi S, Lee SM. Lung cancer in combined pulmonary fibrosis and emphysema: a systematic review and meta-analysis. PLoS One 2016;11:e0161437. doi: 10.1371/journal.pone.0161437

  20. Rajala K, Lehto JT, Saarinen M, Sutinen E, Saarto T, Myllärniemi M. End-of-life care of patients with idiopathic pulmonary fibrosis. BMC Palliat Care 2016;15:85. doi: 10.1186/s12904-016-0158-8

  21. Ahmadi Z, Wysham NG, Lundström S, Janson C, Currow DC, Ekström M. End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study. Thorax 2016;71:510–16. doi: 10.1136/thoraxjnl-2015-207439

  22. Bajwah S. Specialist palliative care is more than drugs: a retrospective study of ILD patients. Lung. 2012;190:215–20. doi: 10.1007/s00408-011-9355-7

  23. Rajala K, Lehto JT, Sutinen E, Kautiainen H, Myllärniemi M, Saarto T. mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis. ERJ Open Res 2017;3:00084-2017. doi: 10.1183/23120541.00084-2017

  24. Yount SE, Beaumont JL, Chen SY, Kaiser K, Wortman K, Van Brunt DL, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. Lung 2016;194:227–34. doi: 10.1007/s00408-016-9850-y

  25. Martinez TY, Pereira CA, dos Santos ML, Ciconelli RM, Guimarães SM, Martinez JA. Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with idiopathic pulmonary fibrosis. Chest 2000;117:1627–32. doi: 10.1378/chest.117.6.1627

  26. Kucuk A, Cumhur Cure M, Cure E. Can COVID-19 cause myalgia with a completely different mechanism? A hypothesis. Clin Rheumatol 2020;39:2103–4. doi: 10.1007/s10067-020-05178-1

  27. van Manen MJ, Birring SS, Vancheri C, Cottin V, Renzoni EA, Russell A-M, et al. Cough in idiopathic pulmonary fibrosis. Eur Respir Rev 2016;25:278–86. doi: 10.1183/16000617.0090-2015

  28. Vainshelboim B. Exercise training in idiopathic pulmonary fibrosis: is it of benefit? Breathe (Sheff) 2016;12:130–8. doi: 10.1183/20734735.006916

  29. Wakwaya Y, Ramdurai D, Swigris JJ. How we do it: managing cough in idiopathic pulmonary fibrosis. Chest 2021;160:1774–82. doi: 10.1016/j.chest.2021.05.071

  30. Booth S, Johnson MJ. Improving the quality of life of people with advanced respiratory disease and severe breathlessness. Breathe 2019;15:199–215. doi: 10.1183/20734735.0200-2019

  31. Lindell KO, Kavalieratos D, Gibson KF, Tycon L, Rosenzweig M. The palliative care needs of patients with idiopathic pulmonary fibrosis: a qualitative study of patients and family caregivers. Heart Lung 2017;46:24–9. doi: 10.1016/j.hrtlng.2016.10.002

  32. Irwin RS. Complications of cough. Chest 2006;129:54S–8S. doi: 10.1378/chest.129.1_suppl.54s

  33. George L, Rehman SU, Khan FA. Diaphragmatic rupture: a complication of violent cough. Chest 2000;117:1200–1. doi: 10.1378/chest.117.4.1200

  34. Panagiotou M, Polychronopoulos V, Strange C. Respiratory and lower limb muscle function in interstitial lung disease. Chron Respir Dis 2016;13:162–72. doi: 10.1177/1479972315626014

  35. Farinacci-Vilaró M, Gerena-Montano L, Nieves-Figueroa H, Garcia-Puebla J, Fernández R, Hernández R, et al. Chronic cough causing unexpected diaphragmatic hernia and chest wall rupture. Radiol Case Rep 2019;15:15–18. doi: 10.1016/j.radcr.2019.10.010

  36. Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Ogawa T, Watanabe F, et al. Quadriceps weakness is related to exercise capacity in idiopathic pulmonary fibrosis. Chest 2005;127:2028–33. doi: 10.1378/chest.127.6.2028

  37. de Paula WD, Rodrigues MP, Ferreira NMC, Passini VV, Melo-Silva CA. Noninvasive assessment of peripheral skeletal muscle weakness in idiopathic pulmonary fibrosis: a pilot study with multiparametric MRI of the rectus femoris muscle. Multidiscip Respir Med 2020;15:707. doi: 10.4081/mrm.2020.707

  38. Wang D, Ma Y, Tong X, Zhang Y, Fan H. Diabetes mellitus contributes to idiopathic pulmonary fibrosis: a review from clinical appearance to possible pathogenesis. Front Public Health 2020;8:196. doi: 10.3389/fpubh.2020.00196

  39. Holland AE. Exercise limitation in interstitial lung disease – mechanisms, significance and therapeutic options. Chron Respir Dis 2010;7:101–11. doi: 10.1177/1479972309354689

  40. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med 2016;194:265–75. doi: 10.1164/rccm.201604-0801CI

  41. Surmachevska N, Tiwari V. Corticosteroid induced myopathy. StatPearls, ed. Treasure Island, FL: StatPearls Publishing; 2022.

  42. Doughty CT, Amato AA. Toxic myopathies. Continuum (Minneap Minn) 2019;25:1712–1731. doi: 10.1212/CON.0000000000000806

  43. Hanada M, Ishimatsu Y, Sakamoto N, Nagura H, Oikawa M, Morimoto Y, et al. Corticosteroids are associated with reduced skeletal muscle function in interstitial lung disease patients with mild dyspnea. Respir Med 2020;174:106184. doi: 10.1016/j.rmed.2020.106184

  44. van Manen MJG, Vermeer LC, Moor CC, Vrijenhoeff R, Grutters JC, Veltkamp M, et al. Clubbing in patients with fibrotic interstitial lung diseases. Respir Med 2017;132:226–31. doi: 10.1016/j.rmed.2017.10.021

  45. Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 2015;46:1113–30. doi: 10.1183/13993003.02316-2014

  46. Herbella FAM, Patti MG. Gastroesophageal reflux disease and idiopathic lung fibrosis. From heartburn to lung transplant, and beyond. Am Surg 2022;88:297–302. doi: 10.1177/0003134821998686

  47. Wang Z, Bonella F, Li W, Boerner EB, Guo Q, Kong X, et al. Gastroesophageal reflux disease in idiopathic pulmonary fibrosis: Uncertainties and controversies. Respiration 2018;96:571–87. doi: 10.1159/000492336

  48. IsHak WW, Wen RY, Naghdechi L, Vanle B, Dang J, Knosp M, et al. Pain and depression: a systematic review. Harv Rev Psychiatry 2018;26:352–63. doi: 10.1097/HRP.0000000000000198

  49. Millan-Billi P, Serra C, Alonso Leon A, Castillo D. Comorbidities, complications and non-pharmacologic treatment in idiopathic pulmonary fibrosis. Med Sci (Basel) 2018;6:59. doi: 10.3390/medsci6030059

  50. Vigeland CL, Hughes AH, Horton MR. Etiology and treatment of cough in idiopathic pulmonary fibrosis. Respir Med 2017;123:98–104. doi: 10.1016/j.rmed.2016.12.016

  51. Morice AH. Chronic cough in idiopathic pulmonary fibrosis: the same difference? Am J Respir Crit Care Med 2022;205:985–6. doi: 10.1164/rccm.202201-0083ED

  52. Bargagli E, Di Masi M, Perruzza M, Vietri L, Bergantini L, Torricelli E, et al. The pathogenic mechanisms of cough in idiopathic pulmonary fibrosis. Intern Emerg Med 2019;14:39–43. doi: 10.1007/s11739-018-1960-5

  53. van Manen MJG, Birring SS, Vancheri C, Vindigni V, Renzoni E, Russell AM, et al. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Eur Respir J 2017;50:1701157. doi: 10.1183/13993003.01157-2017

  54. Azuma A, Taguchi Y, Ogura T, Ebina M, Taniguchi H, Kondoh Y, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011;12:143. doi: 10.1186/1465-9921-12-143

  55. Wijsenbeek MS, Van Beek FT, Geel AL, Van Den Toorn L, Boomars KA, Van Den Blink B, et al. Pirfenidone in daily clinical use in patients with idiopathic pulmonary fibrosis in the Netherlands. Am J Respir Crit Care Med 2013;187:A4340.

  56. Kreuter M, Swigris JJ, Richeldi L, Wijsenbeek M, Nunes H, Suda T, et al. Effects of nintedanib on dyspnoe, cough and quality of life in patients with progressive fibrosing interstitial lung diseases: findings from the INBUILD trial. Pneumologie 2021;75:S24. doi: 10.1055/s-0041-1723308

  57. Bonella F, Wuyts WA, Vancheri C, Russell AM, Lievens D, Stansen W, et al. Effects of nintedanib in patients with idiopathic pulmonary fibrosis and varying severities of cough. Pneumologie 2022;76:S20–1. doi: 10.1055/s-0042-1747732

  58. Hope-Gill BD, Hilldrup S, Davies C, Newton RP, Harrison NK. A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:995–1002. doi: 10.1164/rccm.200304-597OC

  59. Singu B, Verbeeck RK. Should codeine still be considered a WHO essential medicine? J Pharm Pharm Sci 2021;24:329–35. doi: 10.18433/jpps31639

  60. Horton MR, Santopietro V, Mathew L, Horton KM, Polito AJ, Liu MC, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 2012;157:398–406. doi: 10.7326/0003-4819-157-6-201209180-00003

  61. Lutherer LO, Nugent KM, Schoettle BW, Cummins MJ, Raj R, Birring SS, et al. Low-dose oral interferon α possibly retards the progression of idiopathic pulmonary fibrosis and alleviates associated cough in some patients. Thorax 2011;66:446–7. doi: 10.1136/thx.2010.135947

  62. Birring SS, Kavanagh JE, Irwin RS, Keogh KA, Lim KG, Ryu JH, et al. Treatment of interstitial lung disease associated cough: CHEST guideline and expert panel report. Chest 2018;154:904–17. doi: 10.1016/j.chest.2018.06.038

  63. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer paIn: a meta-analysis of effectiveness and side effects. Can Med Assoc J 2006;174:1589–94. doi: 10.1503/cmaj.051528

  64. Allen S, Raut S, Woollard J, Vassallo M. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis. Palliat Med 2005;19:128–30. doi: 10.1191/0269216305pm998oa

  65. Lee J, Lakha SF, Mailis A. Efficacy of low-dose oral liquid morphine for elderly patients with chronic non-cancer paIn: retrospective chart review. Drugs Real World Outcomes 2015;2:369–76. doi: 10.1007/s40801-015-0048-z

  66. Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008;8:287–313. doi: 10.1111/j.1533-2500.2008.00204.x

  67. Winn AN, Check DK, Farkas A, Fergestrom NM, Neuner JM, Roberts AW. Association of current opioid use with serious adverse events among older adult survivors of breast cancer. JAMA Netw Open 2020;3:e2016858. doi: 10.1001/jamanetworkopen.2020.16858

  68. Rasu RS, Sohraby R, Cunningham L, Knell ME. Assessing chronic pain treatment practices and evaluating adherence to chronic pain clinical guidelines in outpatient practices in the United States. J Pain 2013;14:568–78. doi: 10.1016/j.jpain.2013.01.425

  69. Machado GC, Abdel-Shaheed C, Underwood M, Day RO. Non-steroidal anti-inflammatory drugs (NSAIDs) for musculoskeletal pain. BMJ 2021;372:n104. doi: 10.1136/bmj.n104

  70. Freo U, Ruocco C, Valerio A, Scagnol I, Nisoli E. Paracetamol: a review of guideline recommendations. J Clin Med 2021;10:3420. doi: 10.3390/jcm10153420

  71. Derry S, Conaghan P, Da Silva JA, Wiffen PJ, Moore RA. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev 2016;4:CD007400. doi: 10.1002/14651858.CD007400.pub3

  72. Flaherty K, Toews G, Lynch JP 3rd, Kazerooni E, Gross B, Strawerman R, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy and survival. Am J Med 2001;110:278–82. doi: 10.1016/s0002-9343(00)00711-7

  73. Key AL, Holt K, Hamilton A, Smith JA, Earis JE. Objective cough frequency in idiopathic pulmonary fibrosis. Cough 2010;6:4. doi: 10.1186/1745-9974-6-4

  74. Newfield C. New medical indications for thalidomide and its derivatives. Sci J Lander Coll Arts Sci 2018;12:3.

  75. Khor YH, Renzoni EA, Visca D, McDonald CF, Goh NSL. Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns. ERJ Open Res 2019;16:00118-2019. doi: 10.1183/23120541.00118-2019

  76. Alfieri V, Crisafulli E, Visca D, Chong WH, Stock C, Mori L, et al. Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease. Eur Respir J 2020;55:1901681. doi: 10.1183/13993003.01681-2019

  77. Chang CH, Lin HC, Yang CH, Gan ST, Huang CH, Chung FT, et al. Factors associated with exercise-induced desaturation in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2020;15:2643–52. doi: 10.2147/COPD.S272511

  78. Kenn K, Gloeckl R, Heinzelmann I, Kneidinger N. Nonpharmacological interventions: rehabilitation, palliative care and transplantation. In: Costabel U, Crestani B, Wells A, eds. Idiopathic pulmonary fibrosis. Lausanne, CH: ERS Publications; 2016, p. 231–42. doi: 10.1183/2312508X.10006315

  79. Patel AS, Watkin G, Willig B, Mutalithas K, Bellas H, Garrod R, et al. Improvement in health status following cough-suppression physiotherapy for patients with chronic cough. Chron Respir Dis 2011;8:253–8. doi: 10.1177/1479972311422547

  80. Emtner M, Hallin R, Arnardottir RH, Janson C. Effect of physical training on fat-free mass in patients with chronic obstructive pulmonary disease (COPD). Ups J Med Sci 2015;120:52–8. doi: 10.3109/03009734.2014.990124

  81. Chimenti RL, Frey-Law LA, Sluka KA. A mechanism-based approach to physical therapist management of pain. Phys Ther 2018;98:302–14. doi: 10.1093/ptj/pzy030

  82. Hanada M, Kasawara KT, Mathur S, Rozenberg D, Kozu R, Hassan SA, et al. Aerobic and breathing exercises improve dyspnea, exercise capacity and quality of life in idiopathic pulmonary fibrosis patients: systematic review and meta-analysis. J Thorac Dis 2020;12:1041–55. doi: 10.21037/jtd.2019.12.27

  83. Vainshelboim B. Clinical improvement and effectiveness of exercise-based pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: a brief analytical review. J Cardiopulm Rehabil Prev 2021;41: 52–7. doi: 10.1097/HCR.0000000000000544

  84. Arizono S, Taniguchi H, Sakamoto K, Kondoh Y, Kimura T, Kataoka K, et al. Endurance time is the most responsive exercise measurement in idiopathic pulmonary fibrosis. Respir Care 2014;59:1108–15. doi: 10.4187/respcare.02674

  85. Bajwah S, Colquitt J, Loveman E, Bausewein C, Almond H, Oluyase A, et al. Pharmacological and nonpharmacological interventions to improve symptom control, functional exercise capacity and quality of life in interstitial lung disease: an evidence synthesis. ERJ Open Res 2021;7:00107-2020. doi: 10.1183/23120541.00107-2020

  86. Wallaert B, Duthoit L, Drumez E, Behal H, Wemeau L, Chenivesse C, et al. Long-term evaluation of home-based pulmonary rehabilitation in patients with fibrotic idiopathic interstitial pneumonias. ERJ Open Res 2019;5:00045-2019. doi: 10.1183/23120541.00045-2019

  87. Vainshelboim B, Oliveira J, Yehoshua L, Weiss I, Fox BD, Fruchter O, et al. Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. Respiration 2014;88: 378–88. doi: 10.1159/000367899

  88. Ozalevli S, Karaali HK, Ilgin D, Ucan ES. Effect of home-based pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Multidiscip Respir Med 2010;5:31–7. doi: 10.1186/2049-6958-5-1-31

  89. Huppmann P, Sczepanski B, Boensch M, Winterkamp S, Schönheit-Kenn U, Neurohr C, et al. Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J 2013;42:444–53. doi: 10.1183/09031936.00081512

  90. Jastrzebski D, Gumola A, Gawlik R, Kozielski J. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J Physiol Pharmacol 2006;57:139–48.

  91. Holland AE, Hill CJ, Glaspole I, Goh N, McDonald CF. Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respir Med 2012;106:429–35. doi: 10.1016/j.rmed.2011.11.014

Published
2022-07-11
How to Cite
Kašiković Lečić S., Javorac J., Živanović D., Lovrenski A., Tegeltija D., Zvekić Svorcan J., & Maksimović J. (2022). Management of musculoskeletal pain in patients with idiopathic pulmonary fibrosis: a review. Upsala Journal of Medical Sciences, 127(1). https://doi.org/10.48101/ujms.v127.8739